BioMarin Pharmaceutical | BMRN - Net Income


BioMarin Pharmaceutical reported $105.53M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amgen USD 1.82B 486M Mar/2026
Bayer EUR 2.76B 6.52B Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026